SASKATOON, SK, March 28, 2025 /CNW/ – MyKey Global Accommodations, Inc., a premier provider of temporary accommodations for Additional Living Expenses (ALE), Relocation, and Business Travel, is proud to announce the launch of its redesigned website and advanced intelligence vendor management platform. These enhancements support MyKey’s mission to deliver service with E.A.S.E.—Easy, Affordable, Safe, and Enjoyable—while enabling insurance professionals, relocation specialists, and corporate clients to access faster, more efficient, and cost-effective housing solutions.

“Our mission has always been to simplify and enhance the ALE and temporary housing experience for our clients while reducing loss costs for insurance carriers,” said Gordon Doell, Founder and President of OBASA Group and MyKey Global Accommodations, Inc. “With these AI-powered enhancements, we’ve taken efficiency and cost savings to the next level, delivering smarter, more seamless solutions for our partners and their clients.”

The newly released platform introduces a host of features designed to elevate the claims management process and improve user experience for all stakeholders:

Accelerated Claims Resolution – Automated workflows expedite approvals, allowing policyholders to secure suitable accommodations faster.Optimized Cost Management – AI-driven pricing intelligence and built-in policy compliance controls reduce claim leakage and support budget accountability.Enhanced Communication & Transparency – Real-time collaboration among adjusters, service providers, and policyholders fosters improved communication and operational clarity.

These next-generation tools are redefining how temporary housing is sourced, managed, and delivered. By integrating machine intelligence throughout its platform, MyKey empowers users to make informed decisions quickly and efficiently resulting in lower operational costs and improved satisfaction across the board.

As part of its commitment to continuous innovation, MyKey Global Accommodations, Inc. will showcase its latest technological advancements at several major industry events in the coming weeks, including:

– PLRB 2025 Claims Conference & Insurance Services Expo (Booth 1443)
       > March 30 – April 2, 2025 – Indianapolis, IN
– 2025 OIAA Claims Conference (Booth 1104)
       > April 2, 2025 – Toronto, ON
– GBTA Canada Conference 2025
       > April 28 – 30, 2025 – Toronto, ON

Attendees are invited to visit us at one of the aforementioned industry events at the company exhibit booth to experience firsthand how its intelligent systems are transforming temporary housing and claims management.

Top insurance carriers in Canada and United States are currently enjoying early access to these new features and benefits—MyKey is now ready to on-board more customers.

About MyKey Global Accommodations, Inc.

MyKey Global Accommodations, Inc. is a trusted provider of temporary housing solutions for displaced policyholders, relocating employees, and business travelers across North America. Specializing in ALE/Insurance, Relocation, and Business Travel accommodations, MyKey leverages advanced AI technology and an expansive network of verified vendors to deliver reliable, cost-effective, and client-focused service with E.A.S.E.

MyKey Global Accommodations has been revolutionizing the ALE space for the past decade and the company has experienced continuous growth of 200% year over year. To learn more, explore the all-new website at mykey.com.

Media Contact

Shane Kartz
Director of Marketing & Communications
Phone: 1 (306) 955-2221 ext. 416
Email: communications@mykey.com
Website: mykey.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mykey-global-accommodations-inc-unveils-new-website-and-ai-driven-vendor-management-platform-features-to-boost-efficiency-slash-loss-costs-and-revolutionize-temporary-housing-solutions-302414436.html

SOURCE MyKey Global Accommodations

In full year 2024, achieved ₩1,956 billion in consolidated revenue and ₩91 billion in operating profitStrong performance across all business segments, driven by user growth and engagement on the Superapp — now focused on profitable growth

SEOUL, South Korea, March 28, 2025 /PRNewswire/ — Viva Republica, the operator of financial Superapp “Toss,” announced its financial results for the full year 2024, reporting record-high revenue on a consolidated basis, while also achieving first-ever annual net profit in its history.

Consolidated revenue was ₩1,956 billion, up 43% year-over-year. The growth was driven by an expanding user base and its increasing engagement on the Superapp, as well as strong performance across all Consumer services, including Toss Pay, Ads, Trading, Financial Marketplace, and E-commerce. Under its Superapp strategy, Toss continues to offer competitive products across all business segments, generating strong synergy among products. Leveraging its platform-based business model, Toss was also able to rapidly accelerate the growth of its business customer count across advertisers, merchants, sellers, financial institutions, and more. 

Consolidated operating profit came in at ₩91 billion and net profit at ₩21 billion, marking the company’s first full-year of net profitability. This was driven by increased contribution of high-margin Consumer services, as well as the operating leverage Toss has built over the years — a key characteristic it will continue to benefit from as its platform business scales.

As of the end of 2024, the number of Monthly Active Users (MAU) on the Toss Superapp reached 25 million (based on WiseApp data), representing a 29% increase year-over-year. The expanding user base led to higher user engagement across all key Consumer services.

On a standalone basis, Toss recorded ₩587 billion in revenue—which represents a strong year-over-year growth of 75%. It posted operating profit of ₩12 billion and net profit of ₩48 billion — achieving its first-ever full-year net profit on a standalone basis.

“Our achievements this year are a result of the priority shift towards monetization of our platform business. Toss has now structurally transitioned into a stable business generating recurring profit.” said SG Lee, CEO of Toss. “Well rounded growth across all business segments and expanding user base have created a two sided growth flywheel, laying the foundation for profitable growth. We’ve just begun our journey in driving financial growth with business customers and going forward, we will continue to focus on both growth and profitability through user-centric product innovation and platform expansion.”

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/toss-reports-records-revenue-of-2-trillion-krw-and-first-full-year-net-profit-in-2024-302414442.html

SOURCE Viva Republica

In this free webinar, learn about the latest bioanalytical techniques for antibody-drug conjugates (ADCs), antibody-RNA-conjugates (ARCs) and antibody-peptide conjugates, including ligand-binding assays, LC-MS/MS and multiplexing approaches. The featured speakers will share insights into essential PK methods, platform selection strategies and immunogenicity challenges in bioanalysis, supported by real-world case studies. The speakers will also discuss the regulatory requirements for the bioanalysis of conjugated drugs, key reagent selection and strategies to ensure compliance in drug development.

TORONTO, March 28, 2025 /PRNewswire-PRWeb/ — In this webinar, the expert speakers will explore advanced conjugation technologies such as antibody-drug conjugates (ADCs), antibody-RNA-conjugates (ARCs), siRNA/oligos and antibody-peptide conjugates, as well as discuss the best bioanalytical support strategies for these therapies.

Bioanalysis for support of next-generation ADCs and ARCs have exploded recently due to the efficacy and safety that these therapies offer for immuno-oncology, rare diseases, vaccines and potentially many other diseases.

ADCs tend to consist of a toxic small molecule payload attached via a linker to an antibody. The application of these drugs had mainly been in oncology where their mode of action is for the antibody to attach at the desired target site with subsequent release of the small molecule to combat tumor cells. Recently, we have seen a much wider application or use of “ADCs” to other modalities such as antibody-peptide conjugates, ARCs or even other more complicated multi-functional entities.

Having a therapeutic entity with multiple distinct components means that we need to have analytical methodologies for various components. Traditionally, LC-MS/MS has mainly been applied to the quantitation of the small molecule payload or the linker moiety. Ligand-binding assays had been successful for quantitation of the intact ADC or the antibody portion.

The expert speakers will discuss the latest and greatest conjugation technologies (ADCs, ARCs/siRNA/Oligo’s, antibody-peptide conjugates) and how best to support them bioanalytically. Those attending will specifically have the benefit of learning which PK methods are required for bioanalysis of conjugated drugs, various platforms used for PK methods, strategies for selection of the platform to be used for PK methods and PK case studies of conjugated drugs.

Additionally, this webinar will discuss immunogenicity strategies and case studies for support of conjugated drugs. Attendees will also learn what critical reagents are needed/recommended for support of conjugated drugs, challenges with multiplexing PK assays and regulatory expectations. Register for this webinar to learn how best to address these challenges.

Join experts from KCAS Bio, Dominic Warrino, PhD, Senior Director of Scientific Services; and Dawn Dufield, PhD, Scientific Officer, Mass Spectrometry, for the live webinar on Thursday, April 17, 2025, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Cutting-Edge PK and Immunogenicity Strategies for Next-Generation ADCs, ARCs, and Conjugated Biotherapeutics.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com, www.xtalks.com

View original content to download multimedia:https://www.prweb.com/releases/cutting-edge-pk-and-immunogenicity-strategies-for-next-generation-adcs-arcs-and-conjugated-biotherapeutics-upcoming-webinar-hosted-by-xtalks-302414282.html

SOURCE Xtalks